We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros Biostructures Achieve Milestone in Fragment-Based Protein Crystallography Collaboration
News

Proteros Biostructures Achieve Milestone in Fragment-Based Protein Crystallography Collaboration

Proteros Biostructures Achieve Milestone in Fragment-Based Protein Crystallography Collaboration
News

Proteros Biostructures Achieve Milestone in Fragment-Based Protein Crystallography Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Biostructures Achieve Milestone in Fragment-Based Protein Crystallography Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros biostructures GmbH has announced that the first milestone of their research collaboration with Bayer HealthCare in the field of fragment-based protein crystallography has been successfully achieved, triggering the associate milestone payment.

In the collaboration, which started in June 2006, Proteros applies its target know-how, industrial process and proprietary Free Mounting System (FMS™) and Picodropper™ technologies to deliver protein-ligand-structures of active fragments from Bayer HealthCare’s drug discovery programs to Bayer HealthCare. Under the terms of the agreement Proteros will also receive a copy of the jointly selected fragment library for its own use.

”We are pleased to proof that Proteros’ experience, has allowed delivery of valuable protein-fragment-structures to Bayer HealthCare within the envisioned time frame”, stated Torsten Neuefeind, Ph.D., Chief Executive Officer of Proteros.

Advertisement